Oral apixaban + Subcutaneous enoxaparin
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gynecologic Cancer
Conditions
Gynecologic Cancer, Venous Thromboembolism
Trial Timeline
Apr 28, 2015 → Jun 1, 2019
NCT ID
NCT02366871About Oral apixaban + Subcutaneous enoxaparin
Oral apixaban + Subcutaneous enoxaparin is a phase 2 stage product being developed by Bristol Myers Squibb for Gynecologic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02366871. Target conditions include Gynecologic Cancer, Venous Thromboembolism.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02366871 | Phase 2 | Completed |
Competing Products
13 competing products in Gynecologic Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IMGN151 + Carboplatin + Bevacizumab + Olaparib | AbbVie | Phase 2 | 52 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 1 | 33 |
| Atezolizumab + Rucaparib | Roche | Phase 1 | 33 |
| Vigil + Atezolizumab | Roche | Phase 2 | 52 |
| darbepoetin alfa + recombinant human erythropoietin (rHuEPO) | Amgen | Phase 2 | 51 |
| AK112 | Akeso | Phase 2 | 51 |
| Ciprofol + Propofol | Haisco Pharmaceutical Group | Phase 3 | 74 |
| Floseal | Baxter | Phase 3 | 74 |
| FloSeal application | Baxter | Pre-clinical | 20 |
| IPH2201 | Innate Pharma | Phase 1 | 25 |
| Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2) | Alaunos Therapeutics | Phase 1/2 | 33 |
| Neoantigen specific TCR-T cell drug product | Alaunos Therapeutics | Pre-clinical | 15 |